ETF Building Blocks Content Hub Biotech ETFs’ Performance Deserves A Look By Nick Peters-GoldenApril 19, 2023
Innovative ETFs Content Hub Pfizer’s COVID-19 Pill Has Mixed Results for Healthcare ETFs By Max ChenNovember 5, 2021
Innovative ETFs Content Hub A Biotech ETF to Track Nasdaq’s Industry-Setting Benchmark By Max ChenJune 30, 2021
Beyond Basic Beta Content Hub Artificial Intelligence Set to Transform the Pharmaceutical Industry By Ben HernandezJune 1, 2021
Beyond Basic Beta Content Hub Pharma Goes Beyond the Vaccine. ‘PPH’ on the Verge of More Advances By Ben HernandezMarch 4, 2021
Innovative ETFs Content Hub Consider Smaller Biotech ETFs as Big Pharma Goes Shopping in 2021 By Max ChenDecember 31, 2020
Beyond Basic Beta Content Hub Assessing Political Outcomes for Pharmaceuticals ETFs By Tom LydonJuly 21, 2020
Beyond Basic Beta Content Hub Expect Pharmaceuticals M&A Activity to Rebound After COVID-19 Eases By Tom LydonApril 17, 2020
Webcasts An Active ETF Approach to Target Innovations in Next Generation Sequencing By Max ChenNovember 14, 2019
Innovative ETFs Content Hub ACADIA Pharmaceuticals Help Lift Biotech ETFs By Max ChenSeptember 9, 2019
Beyond Basic Beta Content Hub 8 ETFs to Capture Opportunities in Healthcare Sector By Max ChenAugust 22, 2019
Innovative ETFs Content Hub Biotech ETFs Strengthen After Judge Blocks Trump’s Drug Pricing Rule By Max ChenJuly 9, 2019
Innovative ETFs Content Hub AbbVie, Allergan Deal Puts Spotlight on Pharmaceutical ETFs By Max ChenJune 25, 2019
Innovative ETFs Content Hub Pharmaceutical ETFs Break Out on Horizon Pharma’s Positive Drug Results By Max ChenFebruary 28, 2019
Core Equity Content Hub Healthcare ETFs Slip After Abbot Lab’s Revenue Miss, Weak Outlook By Max ChenJanuary 23, 2019
